论文信息 - Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study. - 字舞流文

Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study.

M. Shipp | N. Johnson | J. Radford | P. Zinzani | P. Armand | V. Ribrag | A. Tomita | A. Ricart | M. Fanale | C. Moskowitz | A. Balakumaran | Robert Chen | Yang Wang